GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » ROIC %

Momenta Pharmaceuticals (Momenta Pharmaceuticals) ROIC % : -213.59% (As of Jun. 2020)


View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Momenta Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2020 was -213.59%.

As of today (2024-04-25), Momenta Pharmaceuticals's WACC % is 7.55%. Momenta Pharmaceuticals's ROIC % is -192.81% (calculated using TTM income statement data). Momenta Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Momenta Pharmaceuticals ROIC % Historical Data

The historical data trend for Momenta Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals ROIC % Chart

Momenta Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -131.71 -89.01 -85.20 -138.07 -257.97

Momenta Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -219.14 -156.81 -290.16 -140.83 -213.59

Competitive Comparison of Momenta Pharmaceuticals's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Momenta Pharmaceuticals's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's ROIC % falls into.



Momenta Pharmaceuticals ROIC % Calculation

Momenta Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2019 is calculated as:

ROIC % (A: Dec. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2018 ) + Invested Capital (A: Dec. 2019 ))/ count )
=-311.701 * ( 1 - 0% )/( (123.11 + 118.546)/ 2 )
=-311.701/120.828
=-257.97 %

where

Invested Capital(A: Dec. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=618.365 - 66.796 - ( 521.644 - max(0, 106.104 - 539.127+521.644))
=118.546

Momenta Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2020 is calculated as:

ROIC % (Q: Jun. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2020 ) + Invested Capital (Q: Jun. 2020 ))/ count )
=-229.512 * ( 1 - 0% )/( (112.478 + 102.43)/ 2 )
=-229.512/107.454
=-213.59 %

where

Invested Capital(Q: Mar. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=568.746 - 49.073 - ( 463.234 - max(0, 83.158 - 490.353+463.234))
=112.478

Invested Capital(Q: Jun. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=523.279 - 35.204 - ( 436.298 - max(0, 71.726 - 457.371+436.298))
=102.43

Note: The Operating Income data used here is four times the quarterly (Jun. 2020) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Momenta Pharmaceuticals  (NAS:MNTA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Momenta Pharmaceuticals's WACC % is 7.55%. Momenta Pharmaceuticals's ROIC % is -192.81% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Momenta Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Executives
Bruce Downey director
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner director C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo officer: SVP, Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon officer: Chief Financial & Bus. Officer C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier officer: Chief Mfg and Program Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello officer: Chief HR and Inf. Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning officer: Chief Scientific Officer C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska officer: Chief Accounting Officer (PAO) C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler director, officer: President & CEO